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Strengths and limitations of this study
 ► This will be one of the largest prospective obser-
vational cohort studies including non- valvular atrial 
fibrillation patients investigating the quality of anti-
coagulation with vitamin K antagonists in Spain.
 ► During the follow- up, physical examination data, 
comorbidities, concomitant therapies and results of 
laboratory tests, as well as INR results, changes in 
the anticoagulant therapy, efficacy and safety out-
comes and other adverse events, will be recorded.
 ► All patients will be carefully and prospectively 
followed- up in an observational manner, and no in-
terventions will be performed in relation to the study, 
thus providing an accurate insight from the real clin-
ical practice.
 ► This study is limited by its observational design, the 
inclusion of mostly Caucasian patients and the way 
patients will be managed according to our standard 
protocol of care.
AbStrACt
Introduction Atrial fibrillation (AF) is characterised by a 
high stroke risk. Vitamin K antagonists (VKAs) are the most 
commonly used oral anticoagulants (OACs) in Spain, but 
their efficacy and safety depend on the time in therapeutic 
range of International Normalized Ratio (INR) 2.0–3.0 over 
65%–70%. Unfortunately, the difficulties of maintaining an 
optimal level of anticoagulation and the complications of 
VKAs (particularly haemorrhagic ones), frequently lead to 
cessation of this therapy, which has been associated with 
higher risk of adverse events (AEs), including ischaemic 
stroke. Our aims are as follows: (1) to evaluate the quality 
of oral anticoagulation with VKAs, the prevalence of 
poor quality of anticoagulation, and to identify factors 
predisposing to poor quality anticoagulation; and (2) to 
identify patients who will stop OAC and to investigate what 
factors influence the decision of OAC withdrawal.
Methods and analysis Prospective observational cohort 
study including outpatients newly diagnosed with AF 
and naïve for OACs from July 2016 to June 2018 in an 
anticoagulation clinic. Patients with prosthetic heart valves, 
rheumatic mitral valves or valvular AF will be excluded. 
Follow- up will extend for up to 3 years. During this 
period, the INR results and changes in the anticoagulant 
therapy will be recorded, as well as all AEs, or any other 
information that would be relevant to the proper conduct 
of research.
Ethics and dissemination All patients were informed 
about the nature and purpose of the study, and the 
protocol was approved by the Ethics Committee of Hospital 
General Universitario Morales Meseguer (reference: 
EST:20/16). This is an observational study focusing on ‘real 
life’ practice and therefore all treatments and follow- up 
will be performed in accordance to the routine clinical 
practice with no specific interventions or visits. The results 
of our study will be disseminated by presentations at 
national and international meetings, and publications in 
peer- reviewed journals.
IntroduCtIon
Atrial fibrillation (AF) is the most frequent 
cardiac arrhythmia, with a prevalence of ~2% 
in the overall population, and up to 15% in 
the elderly aged ≥80 years old.1–3
This arrhythmia is characterised by a high 
risk of stroke, but the risk of stroke in AF is 
not homogeneous, being associated with the 
presence of several risk factors that have been 
identified in randomised and observational 
studies.4 The more common and validated 
risk factors are included in the CHA2DS2- 
VASc score, which is used for to determine 
recommendations for stroke prevention.5–7
Oral anticoagulation, either vitamin K 
antagonists (VKAs) or direct- acting oral anti-
coagulants (DOACs), is central for stroke 
prevention in patients with AF. In Spain, the 
most commonly used oral anticoagulants 
(OACs) are the VKAs (acenocoumarol and 
warfarin), since the use of DOACs (dabiga-
tran, rivaroxaban, apixaban and edoxaban) 
is still limited. Nevertheless, VKA therapy 
has a number of complications inherent to 
these drugs such as the interindividual vari-
ability (in relation to clinical and genetic 
factors), pharmacological and food interac-
tions, or the need for systematic monitoring.8 
Therefore, the efficacy and safety of VKAs 
depends on the maintenance of an average 
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Figure 1 Map of Spain and Murcia.
time in therapeutic range (TTR) within an INR 2.0–3.0 
over 65%–70%.9 However, this goal is often not achieved 
in real- world clinical practice. In addition, the initiation 
of VKAs in previously untreated patients is usually asso-
ciated with an increased risk of thromboembolic and 
haemorrhagic complications during the initial period of 
treatment, when the patient is suboptimally protected by 
VKAs.10
Despite oral anticoagulation therapy, cardiovascular 
complications such as acute coronary syndrome and 
cardiovascular death are frequent, due to the coexistence 
of others cardiovascular risk factors such as high blood 
pressure or diabetes mellitus. In addition, thrombotic 
risk correlates with the bleeding risk, and unsurprisingly, 
patients with high CHA2DS2- VASc score also have higher 
risk of bleeding complications.11
Thus, integrated or holistic care of AF includes not 
only stroke prevention but also efforts to reduce cardio-
vascular risk factors, including broader approaches such 
as nurse- led interventions, education and lifestyle modi-
fications (eg, obesity management, exercise and healthy 
lifestyle efforts).12
Unfortunately, the difficulties of maintaining an 
optimal level of anticoagulation and the complications 
of oral anticoagulation with VKAs (particularly haemor-
rhagic ones), frequently lead to cessation of this therapy, 
which has been associated with a higher risk of adverse 
events (AEs), including ischaemic stroke.11 Therefore, 
new prospective studies are necessary to assess the quality 
of oral anticoagulation in VKA users, and second, to inves-
tigate what factors influence decisions on oral anticoagu-
lation therapy and the occurrence of AEs. Third, we will 
determine the influence of a contemporary ‘integrated 
management’ approach to AF on clinical outcomes.
objECtIvES
The following objectives were defined for this study:
1. To evaluate the quality of oral anticoagulation with 
VKAs, the prevalence of poor quality of anticoagula-
tion and to identify factors predisposing to poor quali-
ty anticoagulation.
2. To compare different methods for estimating the qual-
ity of anticoagulation therapy with VKAs (ie, Rosendaal 
method, the direct method, the SD of INR and so on).
3. To develop and refine a prediction scheme to identify 
those patients who will likely have poor anticoagula-
tion quality with VKAs.
4. To analyse the complications and AEs that may arise 
with anticoagulant treatment during the follow- up and 
to find out the predisposing causes in order to estab-
lish potential preventive actions.
5. To identify patients who will stop OACs and to investi-
gate what factors influence the decision of OACs with-
drawal.
6. To assess whether the prediction of bleeding events 
by a strategy based on modifiable bleeding risk factors 
alone is superior to clinical risk scores.
7. To evaluate whether the change in CHA2DS2- VASc 
and HAS- BLED scores between baseline and follow- 
up, would be more predictive of ischaemic stroke and 
bleeding compared with scores assessed at baseline.
8. To investigate the impact of implementing the atri-
al fibrillation better care (ABC: A, avoid stroke with 
OACs; B, better symptom management; C, cardiovas-
cular and comorbidity risk management) pathway, on 
clinical outcomes.
MEthodS And AnAlySIS
Study design
This is a prospective observational cohort study including 
outpatients newly diagnosed with AF and naïve for 
oral anticoagulation in the anticoagulation clinic of 
the Hospital General Universitario Morales Meseguer 
(Murcia, Spain).
hospitals involved and anticoagulation clinic
The ‘Hospital General Universitario Morales Meseguer’ 
is a tertiary hospital located in Murcia City, capital of the 
Autonomous Community of Región de Murcia, in South-
eastern Spain. It is a hospital with 400 beds and almost 
2000 employees, covering an area of ~255 000 inhabitants. 
The ‘Hospital General Universitario Reina Sofía’ is also a 
tertiary hospital located in Murcia City. It has 330 beds 
and ~1800 employees, covering an area of about 200 000 
inhabitants (data revised on January 2019).
The outpatient anticoagulation clinic in the Hospital 
General Universitario Morales Meseguer receives patients 
from both, this hospital and the Hospital General Univer-
sitario Reina Sofía. This anticoagulation clinic is the 
reference clinic for managing patients requiring antico-
agulation from two different health areas, hence covering 
~455 000 inhabitants (figure 1). Of these, 2% receive oral 
anticoagulation therapy with VKAs. Among the multiple 
indications for anticoagulation therapy, non- valvular AF 
is the most frequent, constituting 50% of patients, thus 
we manage approximately a population of 4000 patients 
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with this diagnosis. All patients included in the study were 
derived from this anticoagulation clinic.
Participants
Eligible patients were those who started oral anticoagula-
tion with VKAs for the prevention of thromboembolism 
due to permanent or paroxysmal AF. Only those patients 
older than 18 years with documented evidence of non- 
valvular AF on ECG and not previously anticoagulated 
for another reason were included. Patients with pros-
thetic heart valves, rheumatic mitral valves or other type 
of valvular AF were excluded from this study. In order to 
perform a study that reliably reflects the ‘real world’ clin-
ical practice, no other exclusion criteria were established.
recruitment
From 1 July 2016 to 30 June 2018, all consecutive patients 
referred to the anticoagulation clinic fulfilling the inclu-
sion criteria were selected. Since sampling techniques 
were not used for this study, patients were considered 
included if they met all the selection criteria and accepted 
to participate by signing the informed consent.
baseline assessment
At baseline, a complete medical history was obtained by 
collecting sociodemographic and anthropometric data, 
comorbidities, concomitant therapies and results of the 
most recent lab test. In addition, with the parameters 
recorded, stroke risk (CHADS2 and CHA2DS2- VASc)
5 13 
and bleeding risk (HEMORR2HAGES, HAS- BLED, ATRIA 
and ORBIT)14–17 were calculated. The risk of major 
adverse cardiovascular events (MACEs) was also assessed 
by the 2MACE score.18 The SAMe- TT2R2 score
19 was 
used as an indirect clinical measure of the likelihood of 
achieving a good TTR. Assessment of functional indepen-
dence was performed by the Barthel index for Activities 
of Daily Living20 and the Lawton’s Instrumental Activities 
of Daily Living scale,21 whereas fragility was measured by 
the Clinical Frailty Scale.22
Interventions for the study
This is an observational study focusing on ‘real life’ 
practice; hence, all treatments and follow- up will be 
performed in accordance to the routine clinical practice 
with no specific interventions and no specific visits for 
study purposes. The fact that a patient accepted to partic-
ipate or not in the study will not alter their treatment or 
management.
outcome measures 
Primary outcomes
Ischaemic stroke, major bleeding and all- cause mortality 
are the primary outcomes for this study. Ischaemic stroke 
will be defined as the sudden onset of a focal neurological 
deficit in a location consistent with the territory of a major 
cerebral artery lasting >24 hours or resulted of an obstruc-
tion documented by imaging, surgery or autopsy. Major 
bleeding will be defined according to the 2005 Interna-
tional Society on Thrombosis and Haemostasis (ISTH)23 
criteria as fatal bleeding, and/or symptomatic bleeding in 
a critical area or organ, such as intracranial, intraspinal, 
intraocular, retroperitoneal, intra- articular or pericardial, 
or intramuscular with compartment syndrome, and/or 
bleeding causing a fall in haemoglobin level of ≥20 g/L 
(1.24 mmol/L) or more, or leading to transfusion of ≥2 
units of whole blood or red cells.
Secondary outcomes
Several efficacy and safety secondary outcomes will be 
recorded for this study, including transient ischaemic 
attack (TIA), systemic embolism, venous thromboembo-
lism (deep vein thrombosis and pulmonary embolism), 
acute coronary syndrome, acute heart failure, cardio-
vascular mortality, MACE, clinically relevant non- major 
bleeding (CRNMB) and minor bleeding.
TIA will be defined as a rapid development of clinical 
signs of focal or global cerebral function disturbance, 
lasting <24 hours, with no apparent non- vascular cause 
and confirmed as positive by cerebral imaging. Systemic 
embolism will be considered as any acute vascular occlu-
sion of an organ or limb, documented by images and/
or surgery. Acute heart failure will be determined as a 
gradual or rapid change in heart failure signs and symp-
toms resulting in a need for urgent therapy. A death will be 
classified as cardiac- related when there were unequivocal 
signs that the death occurred by a cardiovascular cause. 
MACE will be defined as the composite of fatal/non- fatal 
myocardial infarction, cardiac revascularisation or cardio-
vascular death. CRNMB will be defined according to the 
2015 ISTH criteria as any sign or symptom of haemor-
rhage that does not fit the criteria for the ISTH defini-
tion of major bleeding but does meet at least one of the 
following criteria: (1) requiring medical intervention by 
a healthcare professional; (2) leading to hospitalisation 
or increased level of care; or (3) prompting a face- to- face 
(ie, not just a telephone or electronic communication) 
evaluation.24 All bleeding reported by the patient that 
will not require medical attention or intervention will be 
considered as minor bleeding. Other outcomes will be 
defined according to the international guidelines. There 
will be no adjudication committee. The investigators will 
identify, confirm and record all AEs.
Sample size estimation
As we stated above, the recruitment was consecutive. We 
intended to include all patients fulfilling the inclusion 
criteria during 2 years but no sample size calculation 
was performed. We performed an estimation based on 
previous projects from our group and average of patients 
starting OACs per year in our clinic. Hence, ~1000 
patients/year start anticoagulant therapy in our clinic, of 
which 60% correspond to patients with AF. We estimated 
an inclusion of at least 500 patients/year.
Statistical analyses
Categorical variables will be expressed as frequencies 
and percentages. Continuous variables will be tested for 
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normality by the Kolmogorov- Smirnov test or the Shapiro- 
Wilk test, and presented as mean±SD or median and IQR, 
as appropriate.
The Pearson χ2 test will be used to compare propor-
tions. Differences between continuous and categorical 
variables will be assessed using the Mann- Whitney U test 
or the Student’s t- test, as appropriate, and correlations 
tested using the Spearman's Rho.
Multivariate Cox proportional hazard regression 
models will be performed to determine the association 
between patients’ characteristics or clinical risk factors 
and AEs (or poor quality of oral anticoagulation). When 
multivariate Cox models will be performed, we will 
include only those variables that showed p value <0.15 in 
the univariate analyses. Goodness of fit will be evaluated 
using the Hosmer- Lemeshow test.
Kaplan- Meier estimates and analysis by the log- rank 
test will be carried out to assess differences in event- free 
survival.
Receiver operating characteristic (ROC) curves will 
be applied to evaluate the predictive ability (expressed 
as c- indexes). Comparisons of ROC curves will be 
carried out as reported by DeLong et al method.25 Net 
reclassification improvement and integrated discrimina-
tory improvement will be performed according to the 
methods described by Pencina et al.26 Finally, clinical 
usefulness and net benefit of new predictive models will 
be estimated using decision curve analyses.27 28
A p value <0.05 will be accepted as statistically signifi-
cant. Statistical analyses will be performed using SPSS 
V.22.0, MedCalc V.16.4.3, STATA V.12.0 and survIDINRI 
package for R V.3.3.1, for Windows.
data collection at baseline and during the follow-up
As previously described, there will be no in- person visits in 
relation to the study. All the information will be captured 
from the electronic medical records, by personal inter-
view using the patients’ routine visits to the anticoagula-
tion clinic and by telephone contact.
During the first visit to the anticoagulation clinic in 
order to start OAC therapy, all eligible patients were 
invited to participate in the study. If they agreed, they had 
to sign an informed consent. This visit was considered as 
the baseline visit. The information described in the Base-
line assessment section was recorded during this visit.
Follow- up will be performed also by personal inter-
view at each routine visit to the outpatient anticoagula-
tion clinic or visits for the anticoagulation control (INR 
measurement). If the patient never attends to these visits, 
medical records and telephone calls will be used to obtain 
the information needed and vital status. In any case, 
patients will never have to attend in- person follow- up 
visits in addition to the routine clinical practice.
Follow- up will extend for up to 3 years, and 30 June 
2021 is the expected date for the last follow- up in the last 
patient included. During this period, the INR results and 
changes in the anticoagulant therapy will be recorded, as 
well as all AEs, or any other information that would be 
relevant to the proper conduct of research.
Regarding the INR results, the therapeutic range for AF 
patients taking VKAs is an INR between 2.0 and 3.0. The 
TTR will be used as a way to assess the quality of antico-
agulation control, and will be calculated by the method 
of Rosendaal29 and by the Proportion of INRs within the 
therapeutic Range (PINRR, also known as direct method) 
at 6 months and 1 year of inclusion. The TTR by the 
method of Rosendaal will be calculated by adding INR 
measurement frequency and their values, and assuming 
that changes between consecutive INR measurements are 
linear over time. The PINRR will evaluate the percentage 
of INR measurements between 2.0 and 3.0 over the total 
number of INR measurements. Poor anticoagulation 
quality will be defined as a TTR <65% by the method of 
Rosendaal or PINRR <60%. The TTR and PINRR will be 
assessed avoiding the first month of anticoagulation since 
this period is largely influenced by the fluctuations due to 
treatment initiation rather due to the anticoagulant itself.
Access to patients’ medical records will be carried 
out through the GOTA software (Systelab Werfen S.A.), 
which is the programme for the INR controls and is 
connected to the electronic medical records programme 
of the Health Service from Murcia (SMS), called SELENE 
(Siemens S.A.). The data records for this study will be 
made on an electronic database.
Premature termination
There are no specified premature termination criteria 
in this study. The management and follow- up will be 
performed according to the routine clinical practice 
and no additional medication, interventions or investiga-
tional medical devices will be applied in this observational 
study. Only those patients who explicitly state that they no 
longer want to be involved in the study, will be withdrawn.
reporting of AEs
During the study, all AEs will be recorded. Serious AEs 
will be reported to the ethical committee in accordance 
to local regulatory requirements.
Ethical considerations and dissemination
All patients likely to be included in the study were informed 
about the nature of the study and received relevant infor-
mation about the intended purpose. As this is an obser-
vational study, no visits have been scheduled in relation 
to the study, and no specific changes will be performed 
regarding the treatment, care or clinical management 
based on the results obtained from this research itself. All 
participants were provided with a unique study number. 
This study number allows the anonymisation of the infor-
mation included in the study database.
The study protocol was carried out in accordance with 
the ethical standards established in the Declaration of 
Helsinki of 1964 and its subsequent amendments. The 
results of our study will be disseminated by presentation 
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at national and international meetings and publication in 
peer- reviewed journals.
Patient and public involvement
Patients and public were not involved in the design, 
recruitment nor conduct of the study.
dISCuSSIon
AF is associated with impaired quality of life, and increased 
mortality and morbidity, mainly due to the embolic risk.30 
Oral anticoagulation is central for the prevention of 
stroke in patients with AF, but a poor quality of anticoagu-
lation with VKAs (ie, a labile INR or a TTR <65%) results 
into a higher risk of AEs.9
Currently, the prescription of DOACs is increasing but 
still remains low in many countries where VKAs are the 
most frequent OACs.31 Therefore, identifying factors that 
lead to poor quality of anticoagulation will allow us to 
identify high- risk patients and to establish clinical inter-
ventions that warrant optimal therapeutic management. 
On the other hand, there are some undesirable effects 
inherent to oral anticoagulation with VKAs (especially 
haemorrhagic ones). Often, these undesirable effects and 
complications of VKAs lead to lower persistence on this 
therapy, which has demonstrated to be associated with a 
higher risk of cardiovascular events, including ischaemic 
stroke.11 For this reason, it is necessary to individually 
assess each patient to find out what factors determine 
decisions about anticoagulant therapy.
To date, the benefits of OACs in AF patients have been 
well demonstrated in randomised clinical trials (RCTs) 
and observational cohorts. However, there are few data, 
in particular from the real world about adherence to 
OACs and causes of poor OACs persistence. Similarly, 
evidence about a prediction strategy based only on modi-
fiable bleeding risk factors, delta CHA2DS2- VASc and 
HAS- BLED scores for the prediction of ischaemic stroke 
and bleeding, and the performance of the ABC pathway 
is scarce, with limited data in a Spanish population.32–38 
Indeed, real- world data are of increasing interest, since 
patients included in the RCTs are, generally different 
from those in real life.39
This study will be limited by its observational design 
and the way the patients will be managed according to 
our standard protocol of care. Nevertheless, all patients 
will be carefully followed- up prospectively, and no inter-
ventions will be done in relation to the study. This will 
provide an accurate insight from the real- world clin-
ical practice. Previously, the first phase of the Murcia 
AF Project resulted in relevant publications in several 
peer- reviewed journals, which have enhanced scientific 
knowledge about different aspects of AF. The present 
protocol paper aims to provide the methodology of the 
second phase of the Murcia AF Project in a stage in which 
four DOACs are available (dabigatran, apixaban, rivar-
oxaban and edoxaban) with prescription rates that are 
increasing, which will allow us to assess the paradigm shift 
in the management of patients with AF.
Current study status
The recruitment of patients started on 1 July 2016 and 
finished on 30 June 2018. During this period, 1291 
patients were screened and 1094 patients were included in 
the study. However, the final sample size is still unknown 
since it will depend on the number of patients that allow 
being followed- up during the 3 years or until death, 
whichever will occur first. Data collection is expected to 
be completed (final follow- up of the last patient) in June 
2021. This manuscript has been prepared following the 
Strengthening the Reporting of Observational Studies in 
Epidemiology checklist.
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